LAFAYETTE, La., April 20, 2017 -- LHC Group, Inc. (NASDAQ:LHCG) announced today details for the release of its results for the first quarter ended March 31, 2017.
LHC Group plans to issue its earnings release for the first quarter ended March 31, 2017, after the market closes on Wednesday, May 3, 2017, and will host a conference call on Thursday, May 4, 2017, at 11:00 a.m. Eastern time. The toll-free number to call for this interactive teleconference is (866) 393-1608 (international callers should call (973) 890-8327). A telephonic replay of the conference call will be available through midnight on Thursday, May 11, 2017, by dialing (855) 859‑2056 (international callers should call (404) 537-3406) and entering confirmation number 6053355.
A live broadcast of LHC Group’s conference call will be available under the Investor Relations section of the Company’s website, www.LHCGroup.com. A one-year online replay will be available approximately an hour following the conclusion of the live broadcast.
About LHC Group, Inc.
LHC Group, Inc. is a national provider of non-acute healthcare services, providing quality, cost‑effective healthcare to patients primarily within the comfort and privacy of their home or place of residence. LHC Group provides a comprehensive array of healthcare services through home health, hospice, community-based services agencies and facility-based services. LHC Group operates 298 home health services locations, 72 hospice locations, 16 community-based service locations and six long-term acute care hospitals (LTACHs) with eight locations.
Certain matters discussed in this press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements about the Company’s future financial performance and the strength of the Company’s operations. Such forward-looking statements may be identified by words such as “continue,” “expect,” and similar expressions. Forward-looking statements involve a number of risks and uncertainties that may cause actual results to differ materially from those expressed or implied by such forward-looking statements, including changes in reimbursement, changes in government regulations, changes in LHC Group’s relationships with referral sources, increased competition for LHC Group’s services, increased competition for joint venture and acquisition candidates, changes in the interpretation of government regulations and other risks set forth in Item 1A. Risk Factors in LHC Group’s Annual Report on Form 10-K for the year ended December 31, 2015, filed with the Securities and Exchange Commission. LHC Group undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Contact: Eric Elliott Senior Vice President of Finance (337) 233-1307 [email protected]


Elon Musk Seeks $134 Billion in Lawsuit Against OpenAI and Microsoft Over Alleged Wrongful Gains
One Percent Rule Checklist For Safer Forex Trading Risk
Syrah Resources and Tesla Extend Deadline on Graphite Supply Dispute to March
Micron to Buy Powerchip Fab for $1.8 Billion, Shares Surge Nearly 10%
China Considers New Rules to Limit Purchases of Foreign AI Chips Amid Growing Demand
Boeing Reaches Tentative Labor Deal With SPEEA Workers After Spirit AeroSystems Acquisition
Walmart International CEO Kathryn McLay to Step Down After Two and a Half Years
xAI Restricts Grok Image Editing After Sexualized AI Images Trigger Global Scrutiny
Publishers Seek to Join Lawsuit Against Google Over Alleged AI Copyright Infringement
Federal Judge Clears Way for Jury Trial in Elon Musk’s Fraud Lawsuit Against OpenAI and Microsoft
Google Seeks Delay on Data-Sharing Order as It Appeals Landmark Antitrust Ruling
China’s AI Models Narrow the Gap With the West, Says Google DeepMind CEO
Anthropic Appoints Former Microsoft Executive Irina Ghose to Lead India Expansion
TSMC Shares Hit Record High as AI Chip Demand Fuels Strong Q4 Earnings
Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio 



